glp 1 based therapies GLP-1-based for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 therapy appears to reduce

T lymphocytes, which release pro-inflammatory cytokines, play a particular role in this phenomenon [73]

Modern GLP-1 analogues are designed to minimise immunogenicity, and neutralising antibodies rarely drive complete non-response

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 261,46 per year only 21,79 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Yerba Mate 10:1 Extract

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study) Trials